Cancer Treatment News and Research

RSS

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

The George W. Bush Institute is forming a public-private partnership to use PEPFAR's existing infrastructure of doctors, nurses and clinics to expand screening and treatment of women for cervical cancer and perform breast cancer education in the developing world, the Wall Street Journal reports.

13 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

Study identifies genes never before linked to antibiotic resistance in enterococci

An analysis of the genome of a superbug has yielded crucial, novel information that could aid efforts to counteract the bacterium's resistance to an antibiotic of last resort.

9 Sep 2011

Studies examine overuse of scans in determining status of prostate cancer

During Prostate Cancer Awareness Month, researchers will publish the findings of two studies examining the use, or overuse, of scans in determining the status or level of a patient's prostate cancer after diagnosis. "Typically, patients with an elevated PSA level undergo a prostate biopsy to confirm the presence of cancer.

8 Sep 2011

SFDA approves MedWaves' AveCure microwave coagulation-ablation system for cancer

MedWaves' AveCure microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions safely, effectively, precisely and with repeatability.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

ACS' Commission on Cancer releases new standards to directly address patient concerns

A patient-centered approach is at the forefront of new accreditation standards for hospital cancer programs released today by the Commission on Cancer (CoC) of the American College of Surgeons.

2 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Radiation can make cancer cells resistant to radio- and chemotherapy. University of Oslo researchers have now figured out how resistance can be switched on and off.

30 Aug 2011

Medical engineers develop sensor chip to monitor cancerous tumors

A surgery is usually one of the first therapy options in cancer treatment. However, some tumors, such as brain tumors, can be difficult to operate on if there is a risk of damaging surrounding nerve tissue.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Long-term effects of chemotherapy on women's reproductive health

Current estimates of the impact of chemotherapy on women's reproductive health are too low, according to a University of California, San Francisco (UCSF) study.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

Cancer Treatment News and Research

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Study identifies genes never before linked to antibiotic resistance in enterococci

Studies examine overuse of scans in determining status of prostate cancer

SFDA approves MedWaves' AveCure microwave coagulation-ablation system for cancer

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

ACS' Commission on Cancer releases new standards to directly address patient concerns

FDA approves crizotinib for treatment of ALK-positive lung cancer

Engineered virus shows promise in cancer therapy via bloodstream

Biophysicists discover how to turn body's own resistance to radiation treatment on and off

Medical engineers develop sensor chip to monitor cancerous tumors

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Long-term effects of chemotherapy on women's reproductive health

MDxHealth first half 2011 commercial revenues increase 19%

KU professor to create patient-friendly lung cancer treatment

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News